Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49 Years

The purpose of this study is to test an investigational vaccine known as "VAX161B". VAX161B
is a vaccine for the influenza A virus subtype H5N1 avian influenza virus (bird flu). In
this study, the subject will receive the VAX161B vaccine at one of five doses to see which
does might be the best. VaxInnate want to find out how safe these vaccines are and how well
they are tolerated by people who receive them. To measure how effective each type of
vaccine is, VaxInnate will test the ability of the body to develop an immune response, which
means how well the body recognizes and defends itself against the influenza virus.

Inclusion Criteria:

- male or female aged 18 - 49 years inclusive

- give written informed consent to participate

- healthy, as determined by medical history, physical examination

- comprehension of the study requirements

- willing to provide multiple blood specimens collected by venipuncture.

Exclusion Criteria:

- Subjects who have a psychiatric illness, a chronic illness that would interfere with
participation or interpretation of results

- clinically significant abnormal liver function tests

- positive serology for HBsAg or HCV antibodies

- impaired immune responses

- history of anaphylactic type reaction to injected vaccines

- history of drug or chemical abuse in the year prior to screening

- history of Guillain-Barré Syndrome

- history of chronic obstructive pulmonary disease or history of other lung disease